Chronic Rhinosinusitis Trial, Completed NCT01778465 Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's Condition: Chronic Rhinosinusitis
Back to Chronic Rhinosinusitis

Trial results

AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

According to the results reported on ClinicalTrials.gov, this trial involved 7 participants in total — 3 in one group and 4 in the other. It used a "crossover" design, meaning everyone tried both approaches: one group followed a low-salicylate diet for 7 days first, then switched to a normal diet for 7 days, while the other group did it in the opposite order. Salicylates are natural chemicals found in many foods. The trial was measuring several things in participants' urine, as well as their self-reported sinus and nasal symptoms. The reported data shows the following urine measurements after each diet period. For a substance called cys-leukotrienes (chemicals linked to inflammation), levels were 874.05 pg/ml on the low-salicylate diet and 771.99 pg/ml on the normal diet. For salicyluric acid (a breakdown product of salicylates), levels were 44.21 ng/ml on the low-salicylate diet and 23.82 ng/ml on the normal diet. For salicylic acid itself, levels were 0.60 ng/ml on the low-salicylate diet and 0.92 ng/ml on the normal diet. Creatinine (a substance used to help interpret urine tests) was measured at 9.9 mmol/L on the low-salicylate diet and 15.3 mmol/L on the normal diet. The reported data also shows results from a symptom questionnaire called the SNOT-22, which asks people to rate 22 sinus and nasal symptoms on a scale from 0 (no problem) to 5 (as bad as it can be), giving a total possible score of 0 to 110 — where a higher score means worse symptoms. Participants reported an average score of 44 during the low-salicylate diet period and 66 during the normal diet period. It is worth noting that only 7 people completed this trial, which is a very small number, and the data as submitted does not include any further statistical analysis of these results. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.

These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.

Chronic Rhinosinusitis Trial, Completed

NCT01778465
Completed Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are an adult (18 years or older)
  • You have a condition called Aspirin-exacerbated respiratory disease, which means your breathing symptoms get worse when you take aspirin or similar pain medications

Who may not be able to join:

  • You have taken Prednisone or other steroid tablets/injections more than 3 times in the past 3 months
  • You have had sinus surgery or nasal polyp removal surgery within the past 6 months
  • You have another serious ongoing illness, such as kidney failure or a condition that weakens your immune system

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Completed
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 May 2013
Est. completion
1 March 2014

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Urinary Levels of Cys-Leukotrienes; Urinary Salicyluric Acid Levels; Urinary Salicylic Acid Levels; Urinary Creatinine Levels

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov